MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable
neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants
will receive mirdametinib (PD-0325901).